November 7, 2019 (Waterloo, ON) — Today, Deloitte Technology Fast 50™ program announced its 2019 award recipients ranking Intellijoint Surgical® as 2nd for its rapid revenue growth, entrepreneurial spirit and bold innovation. The program recognizes Canada’s 50 fastest-growing technology companies with the highest revenue-growth percentage over the past four years. Intellijoint Surgical made this prestigious list with a 10,247 percent in revenue growth from 2015 to 2018! MORE>>
Toronto, Canada (November 6, 2019) — At Export Development Canada’s kickoff to Cleantech Export Week, Vive Crop Protection was recognized as one of a select group of cleantech companies whose technologies and business strategies have succeeded in getting their products beyond Canada’s borders. MORE>>
NOVARI HEALTH’S EREFERRAL, CENTRAL INTAKE, AND WORKFLOW MANAGEMENT SOLUTION IS LIVE AT LONDON HEALTH SCIENCE CENTRE AND THE SOUTH WEST REGION OF ONTARIO
November 4, 2019 — Novari Health eRequest™, an eReferral, central intake and workflow management module has gone live at London Health Science Centre and other participating hospitals in the south west region of the province.
Implementations of the same Novari Health technology have proven to be impactful in the central west, central, Mississauga Halton, north west, and now the south west region of the province. This region is the sixth to successfully implement the Novari Health Access to Care software platform, and specifically the Novari eRequest module. Across these regions, the technology has been implemented for a mix of central intake and workflow management of hip, knee, shoulder, foot, ankle, spine, low back, rehabilitation/complex care, diabetes, and mental health referrals. MORE>>
TORONTO, Ontario and CAMBRIDGE, MA. — October 24, 2019 — ProMIS Neurosciences, Inc. (TSX: PMN) (OTCQB: ARFXF), a biotechnology company focused on the discovery and development of antibody therapeutics targeting toxic oligomers implicated in the development of neurodegenerative diseases, has issued a memorandum, compiled by its Executive Chairman of the Board, that provides context for the company’s recent program progress as well as a white paper analysis of Biogen’s October 22, 2019 decision to submit its amyloid-beta (Aβ)-targeting drug candidate, aducanumab for Alzheimer’s disease (AD) to the U.S. Food and Drug administration (FDA) in early 2020. The new resources detail how each development demonstrates strong momentum across the company’s preclinical programs. MORE>>
TORONTO, Ontario and CAMBRIDGE, Mass. — October 23, 2019 — ProMIS Neurosciences, Inc. (TSX: PMN) (OTCQB: ARFXF), a biotechnology company focused on the discovery and development of antibody therapeutics targeting toxic oligomers implicated in the development of neurodegenerative diseases, has generated antibody candidates targeting the neurotoxic form of TAR DNA-binding protein 43 (TDP-43), a protein found in all cells and implicated as a root cause in a spectrum of diseases such as amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD). MORE>>